TABLE 4.
Efficacy of sordarin derivatives against pneumocystosis in rats
| Compounda | Dose (mg/kg) | Log no. of cysts/g of lungb | Reduction in log | % Reduction |
|---|---|---|---|---|
| Control | 7.6 ± 0.2 | |||
| GM193663 | 0.1 | 6.7 ± 0.9 | 0.9 | 89.81 |
| 1.0 | 4.7 ± 0.2* | 2.9 | 99.90 | |
| 5.0 | 4.8 ± 0.3* | 2.8 | 99.86 | |
| GM237354 | 0.1 | 5.8 ± 0.9* | 1.8 | 99.82 |
| 1.0 | 4.6 ± 0.1* | 3.0 | 99.98 | |
| 5.0 | 3.4 ± 0.2* | 4.2 | 99.99 |
a
Sordarin derivatives were administered subcutaneously every 12 h for 10 consecutive days.
b
*, P value of <0.05 for mean log of cysts in treated versus control group by Student-Newman Keuls multiple comparison procedure. Values are means ± standard deviations.